Orforglipron News — every source, one live feed
Track Orforglipron news in real time — Lilly's daily weight-loss pill approaching approval and mass availability. fllwup^ collects the latest Orforglipron headlines from every major source into one live feed — free, no account, no algorithm. Coverage aggregated from BBC, Reuters, AP, NYT, TechCrunch, Al Jazeera, and 200+ other outlets.
Latest Orforglipron headlines
- While Not the First Oral GLP-1, Daily Orforglipron Pill Could Reduce Reliance on Weight Loss Injections — Discover Magazine
- 9 Foundayo (Orforglipron) Side Effects You Should Know About — GoodRx
- Weight-loss pills: can orforglipron preserve weight loss after Mounjaro? — British Heart Foundation
- Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial — Nature
- What Is Orforglipron? Inside a CU Anschutz Clinical Trial for a New Oral GLP-1 Weight-Loss Drug — University of Colorado Anschutz
- Orforglipron offers greater weight loss for people with diabetes than oral semaglutide — The Pharmaceutical Journal
- Lilly's oral GLP-1 Foundayo (orforglipron) delivered superior A1C control and weight loss in three pivotal type 2 diabetes trials — Eli Lilly and Company
- Pharmacokinetic Bioequivalence of Orforglipron Tablets and Capsules in Healthy Participants With Obesity or Overweight — National Institutes of Health (NIH) | (.gov)
- UK first in Europe to authorise orforglipron for weight management and type 2 diabetes — GOV.UK
- What to Know About Foundayo, the New Pill GLP-1 for Weight Loss — Health US News
Follow Orforglipron live on fllwup^ — or browse all topics.
More Health & Medicine: browse the category. Compare: fllwup^ vs Flipboard · vs Feedly · vs Google News · vs Apple News.